Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Lung Cancer | Systematic Review

Pretreatment quality of life and survival in patients with lung cancer: a systematic review and meta-analysis

Authors: Taro Okayama, Katsuyoshi Suzuki, Shinichiro Morishita, Junichiro Inoue, Takashi Tanaka, Jiro Nakano, Takuya Fukushima

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Although many studies have explored the correlation between quality of life and survival, none have reported this relationship for specific cancers assessed at distinct time points. This meta-analysis aimed to investigate the impact of pretreatment Global Quality of Life (QOL) and functioning QOL, including physical, social, role, emotional, and cognitive QOLs, on mortality risk in patients with lung cancer.

Methods

A literature search was conducted across the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Scopus, and PubMed databases for articles published between their inception and December 2022. Subsequently, 11 studies were selected based on predefined eligibility criteria to investigate the relationship between pretreatment QOLs and mortality risk in patients with lung cancer.

Results

Pretreatment global, physical, social, role, and emotional QOLs were significantly associated with mortality risk as follows: Global QOL (hazard ratio [HR] = 1.08 95% confidence interval [CI] = 1.03–1.13); Physical QOL (HR = 1.04 95% CI = 1.02–1.05); Social QOL (HR = 1.02 95% CI = 1.01–1.03; Role QOL (HR = 1.01 95% CI = 1.01–1.02); Emotional QOL (HR = 1.01 95% CI = 1.00–1.03).

Conclusions

These findings underscore the importance of early QOL assessment after diagnosis as well as early provision of physical, social, and psychological support accommodating each patient’s demands.

Trial registration

The International Prospective Register of Systematic Reviews registration number CRD42023398206, Registered on February 20, 2023.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.PubMedCrossRef
2.
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–75.PubMedPubMedCentralCrossRef
3.
Bade B, Dela CC. Lung Cancer 2020: Epidemiology, etiology, and prevention. Clin Chest Med. 2020;41:1–24.PubMedCrossRef
4.
Hung J-J, Jeng W-J, Hsu W-H, Chou T-Y, Huang B-S, Wu Y-C. Predictors of death, local recurrence, and distant metastasis in completely resected pathological Stage-I non–small-cell lung cancer. J Thorac Oncol. 2012;7:1115–23.PubMedCrossRef
5.
The WHOQOL Group. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41(10):1403–9.
6.
Sloan JA, Cheville AL, Liu H, Novotny PJ, Wampfler JA, Garces YL, et al. Impact of self-reported physical activity and health promotion behaviors on lung cancer survivorship. Health Qual Life Outcomes. 2016;14:66.PubMedPubMedCentralCrossRef
7.
Kristensen A, Grønberg BH, Fløtten Ø, Kaasa S, Solheim TS. Trajectory of health-related quality of life during the last year of life in patients with advanced non-small–cell lung cancer. Support Care Cancer. 2022;30:9351–8.PubMedPubMedCentralCrossRef
8.
Chabowski M, Polański J, Mazur G, Janczak D, Rosińczuk J. Clinical Management of Pulmonary Disorders and Diseases. Advances in Experimental Medicine and Biology, vol 1022. In: Pokorski M, editor. Sociodemographic and Clinical Determinants of Quality of Life of Patients with Non-small Cell Lung Cancer. Cham: Springer; 2017. p. 1–10.
9.
van Vulpen JK, Hiensch AE, van Hillegersberg R, Ruurda JP, Backx FJG, Nieuwenhuijzen GAP, et al. Supervised exercise after oesophageal cancer surgery: the PERFECT multicentre randomized clinical trial. Br J Surg. 2021;108:786–96.PubMedPubMedCentralCrossRef
10.
Liu W, Zhang Q, Zhang T, Li L, Xu C. Quality of life in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis. World J Surg Oncol. 2022;20:333.PubMedPubMedCentralCrossRef
11.
Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318:197–8.PubMedPubMedCentralCrossRef
12.
Yang LY, Manhas DS, Howard AF, Olson RA. Patient-reported outcome use in oncology: a systematic review of the impact on patient-clinician communication. Support Care Cancer. 2018;26:41–60.PubMedCrossRef
13.
Hilarius DL, Kloeg PH, Gundy CM, Aaronson NK. Use of health-related quality-of-life assessments in daily clinical oncology nursing practice. Cancer. 2008;113:628–37.PubMedCrossRef
14.
Yamashita H, Omori M, Okuma K, Kobayashi R, Igaki H, Nakagawa K. Longitudinal assessments of quality of life and late toxicities before and after definitive chemoradiation for esophageal cancer. Jpn J Clin Oncol. 2014;44:78–84.PubMedCrossRef
15.
Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26:1355–63.PubMedCrossRef
16.
Mauer ME, Bottomley A, Coens C, Gotay C. Prognostic factor analysis of health-related quality of life data in cancer: a statistical methodological evaluation. Expert Rev Pharmacoecon Outcomes Res. 2008;8:179–96.PubMedCrossRef
17.
Quinten C, Coens C, Mauer M, Comte S, Sprangers MAG, Cleeland C, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10:865–71.PubMedCrossRef
18.
van Nieuwenhuizen AJ, Buffart LM, Brug J, Leemans CR, Verdonck-de Leeuw IM. The association between health related quality of life and survival in patients with head and neck cancer: a systematic review. Oral Oncol. 2015;51:1–11.PubMedCrossRef
19.
Husson O, de Rooij B, Kieffer J, Oerlemans S, Mols F, Aaronson N, et al. The EORTC QLQ-C30 Summary score as prognostic factor for survival of patients with cancer in the “real-world”: results from the population-based PROFILES registry. Oncologist. 2020;25(4):e722–32.PubMedCrossRef
20.
Zikos E, Coens C, Quinten C, Ediebah D, Martinelli F, Ghislain I, et al. The added value of analyzing pooled health-related quality of life data: a review of the EORTC PROBE initiative. J Natl Cancer Inst. 2016;108(5):djv391.PubMedCrossRef
21.
Qi Y, Schild S, Mandrekar S, Tan A, Krook J, Rowland K, et al. Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. J Thorac Oncol. 2009;4(9):1075–82.PubMedPubMedCentralCrossRef
22.
Sloan J, Zhao X, Novotny P, Wampfler J, Garces Y, Clark M, et al. Relationship between deficits in overall quality of life and non-small-cell lung cancer survival. J Clin Oncol. 2012;30(13):1498–504.PubMedPubMedCentralCrossRef
23.
Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71-n.CrossRef
24.
Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.PubMedCrossRef
25.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.PubMedCrossRef
26.
Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.PubMedCrossRef
27.
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.PubMedCrossRef
28.
29.
30.
Badaoui S, Shahnam A, McKinnon R, Abuhelwa A, Sorich M, Hopkins A. The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy. Transl Lung Cancer Res. 2022;11(3):432–9.PubMedPubMedCentralCrossRef
31.
Langendijk H, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Wouters M. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol. 2000;55(1):19–25.PubMedCrossRef
32.
Movsas B, Moughan J, Sarna L, Langer C, Werner Wasik M, Nicolaou N, et al. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol. 2009;27(34):5816–22.PubMedPubMedCentralCrossRef
33.
Pompili C, Omar S, Ilyas M, Velikova G, Dalmia S, Valuckiene L, et al. Patient-reported physical function is associated with survival after lung resection for non-small cell lung cancer. Ann Thorac Surg. 2022;116:563–9.
34.
Reck M, Thatcher N, Smit E, Lorigan P, SzutowiczZielinska E, Liepa A, et al. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. Lung Cancer. 2012;78(3):276–81.PubMedCrossRef
35.
Fielding R, Wong W. Quality of life as a predictor of cancer survival among Chinese liver and lung cancer patients. Eur J Cancer. 2007;43(11):1723–30.PubMedCrossRef
36.
Nieto-Guerrero Gómez JM, Silva Vega GP, Cacicedo J, Delgado León BD, Herrero Rivera D, Praena Fernández JM, et al. Impact of pre-radiation therapy quality of life in lung cancer survival: a prospective, intention-to-treat, multicenter study. Clin Transl Oncol. 2020;22(9):1635–44.PubMedCrossRef
37.
Pinheiro L, Reeve B. Investigating the prognostic ability of health-related quality of life on survival: a prospective cohort study of adults with lung cancer. Support Care Cancer. 2018;26(11):3925–32.PubMedCrossRef
38.
Trejo M, Bell M, Dhillon H, Vardy J. Baseline quality of life is associated with survival among people with advanced lung cancer. J Psychosoc Oncol. 2020;38(5):635–41.PubMedPubMedCentralCrossRef
39.
Möller A, Sartipy U. Associations between changes in quality of life and survival after lung cancer surgery. J Thorac Oncol. 2012;7(1):183–7.PubMedCrossRef
40.
Ediebah D, Quinten C, Coens C, Ringash J, Dancey J, Zikos E, et al. Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials. Cancer. 2018;124(16):3409–16.PubMedCrossRef
41.
Bade B, Brooks M, Nietert S, Ulmer A, Thomas DD, Nietert P, et al. Assessing the correlation between physical activity and quality of life in advanced lung cancer. Integr Cancer Ther. 2018;17(1):73–9.PubMedCrossRef
42.
Penttinen H, Utriainen M, Kellokumpu Lehtinen P-L, Raitanen J, Sievänen H, Nikander R, et al. Effectiveness of a 12-month exercise intervention on physical activity and quality of life of breast cancer survivors; Five-year results of the BREX-study. In Vivo. 2019;33(3):881–8.PubMedPubMedCentralCrossRef
43.
Wang J-W, Gong X-H, Ding N, Chen X-F, Sun L, Tang Z, et al. The influence of comorbid chronic diseases and physical activity on quality of life in lung cancer survivors. Support Care Cancer. 2015;23(5):1383–9.PubMedCrossRef
44.
Larsson M, Ljung L, Johansson BBK. Health-related quality of life in advanced non-small cell lung cancer: correlates and comparisons to normative data. Eur J Cancer Care. 2012;21(5):642–9.CrossRef
45.
D’Silva A, Gardiner P, Boyle T, Bebb DG, Johnson S, Vallance J. Associations of objectively assessed physical activity and sedentary time with health-related quality of life among lung cancer survivors: A quantile regression approach. Lung Cancer. 2018;119:78–84.PubMedCrossRef
46.
Okayama T, Naito T, Yonenaga Y, Ohashi T, Kitagawa M, Mitsuhashi N, et al. Clinical impact of walking capacity on the risk of disability and hospitalizations among elderly patients with advanced lung cancer. Support Care Cancer. 2021;29(7):3961–70.PubMedCrossRef
47.
Marjanski T, Badocha M, Wnuk D, Dziedzic R, Ostrowski M, Sawicka W, et al. Result of the 6-min walk test is an independent prognostic factor of surgically treated non-small-cell lung cancer. Interact Cardiovasc Thorac Surg. 2019;28(3):368–74.PubMedCrossRef
48.
Friedenreich C, Stone C, Cheung W, Hayes S. Physical activity and mortality in cancer survivors: a systematic review and meta-analysis. JNCI Cancer Spectr. 2020;4(1):pkz080.PubMedCrossRef
49.
Burtin C, Bezuidenhout J, Sanders KJC, Dingemans A-M, Schols AMWJ, Peeters STH, et al. Handgrip weakness, low fat-free mass, and overall survival in non-small cell lung cancer treated with curative-intent radiotherapy. J Cachexia Sarcopenia Muscle. 2020;11(2):424–31.PubMedPubMedCentralCrossRef
50.
Yang M, Shen Y, Tan L, Li W. Prognostic value of sarcopenia in lung cancer: a systematic review and meta-analysis. Chest. 2019;156(1):101–11.PubMedCrossRef
51.
Deng H-Y, Hou L, Zha P, Huang K-L, Peng L. Sarcopenia is an independent unfavorable prognostic factor of non-small cell lung cancer after surgical resection: a comprehensive systematic review and meta-analysis. Ejso. 2019;45(5):728–35.PubMedCrossRef
52.
Jensen S, Bloch Z, Quist M, Hansen TTD, Johansen C, Pappot H, et al. Sarcopenia and loss of muscle mass in patients with lung cancer undergoing chemotherapy treatment: a systematic review and meta-analysis. Acta Oncol. 2023;62(3):318–28.PubMedCrossRef
53.
Naito T, Mitsunaga S, Miura S, Tatematsu N, Inano T, Mouri T, et al. Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer. J Cachexia Sarcopenia Muscle. 2019;10(1):73–83.PubMedCrossRef
54.
Temel J, Greer J, Muzikansky A, Gallagher E, Admane S, Jackson V, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–42.PubMedCrossRef
55.
Lu Y, Bai X, Pan C. Impact of exercise interventions on quality of life and depression in lung cancer patients: A systematic review and meta-analysis. Int J Psychiatry Med. 2024;59(2):199–217.
56.
Janssens A, Derijcke S, Galdermans D, Daenen M, Surmont V, De Droogh E, et al. Prognostic understanding and quality of life in patients with advanced lung cancer: a multicenter study. Clin Lung Cancer. 2019;20(3):e369–75.PubMedCrossRef
57.
Nishiura M, Tamura A, Nagai H, Matsushima E. Assessment of sleep disturbance in lung cancer patients: relationship between sleep disturbance and pain, fatigue, quality of life, and psychological distress. Palliat Support Care. 2015;13(3):575–81.PubMedCrossRef
58.
Gil F, Costa G, Hilker I, Benito L. First anxiety, afterwards depression: psychological distress in cancer patients at diagnosis and after medical treatment. Stress Health. 2012;28(5):362–7.PubMedCrossRef
59.
Papadopoulou A, Govina O, Tsatsou I, Mantzorou M, Mantoudi A, Tsiou C, et al. Quality of life, distress, anxiety and depression of ambulatory cancer patients receiving chemotherapy. Med Pharm Rep. 2022;95(4):418–29.PubMedPubMedCentral
60.
Polański J, Chabowski M, Chudiak A, Uchmanowicz B, Janczak D, Rosińczuk J, et al. Intensity of anxiety and depression in patients with lung cancer in relation to quality of life. Adv Exp Med Biol. 2018;1023:29–36.PubMedCrossRef
61.
van Montfort E, de Vries J, Arts R, Aerts J, Kloover J, Traa M. The relation between psychological profiles and quality of life in patients with lung cancer. Support Care Cancer. 2020;28(3):1359–67.PubMedCrossRef
62.
Luszczynska A, Pawlowska I, Cieslak R, Knoll N, Scholz U. Social support and quality of life among lung cancer patients: a systematic review. Psycho Oncol. 2013;22(10):2160–8.CrossRef
63.
Li Q, Lin Y, Qiu Y, Gao B, Xu Y. The assessment of health-related quality of life and related factors in Chinese elderly patients undergoing chemotherapy for advanced cancer: a cross-sectional study. Eur J Oncol Nurs. 2014;18(4):425–35.PubMedCrossRef
64.
Zimmermann C, Burman D, Swami N, Krzyzanowska M, Leighl N, Moore M, et al. Determinants of quality of life in patients with advanced cancer. Support Care Cancer. 2011;19(5):621–9.PubMedCrossRef
65.
Polanski J, Jankowska Polanska B, Rosinczuk J, Chabowski M, Szymanska CA. Quality of life of patients with lung cancer. Onco Targets Ther. 2016;9:1023–8.PubMedPubMedCentral
66.
Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer. 2001;31(2–3):233–40.PubMedCrossRef
67.
Levinsen AKG, Dalton S, Andersen I, Mellemgaard A, Oksen M, Saltbæk L, et al. Association between health-related quality of life and completion of first-line treatment among lung cancer patients. Cancers (Basel). 2022;14(14):3343.PubMedCrossRef
68.
Brocken P, van der Heijden EHFM, Oud KTM, Bootsma G, Groen HJM, Donders ART, et al. Distress in suspected lung cancer patients following rapid and standard diagnostic programs: a prospective observational study. Psycho Oncol. 2015;24(4):433–41.CrossRef
69.
Moseholm E, Rydahl Hansen S, Overgaard D, Wengel HS, Frederiksen R, Brandt M, et al. Health-related quality of life, anxiety and depression in the diagnostic phase of suspected cancer, and the influence of diagnosis. Health Qual Life Outcomes. 2016;14:80.PubMedPubMedCentralCrossRef
70.
Luo N, Fones CS, Lim SE, Xie F, Thumboo J, Li SC. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30): validation of English version in Singapore. Qual Life Res. 2005;14:1181–6.PubMedCrossRef
71.
Pompili C, Brunelli A, Xiumé F, Refai M, Salati M, Socci L, et al. Prospective external convergence evaluation of two different quality-of-life instruments in lung resection patients. Eur J Cardiothorac Surg. 2011;40:99–105.PubMedCrossRef
72.
Holzner B, Kemmler G, Sperner-Unterweger B, Kopp M, Dünser M, Margreiter R, et al. Quality of life measurement in oncology–a matter of the assessment instrument? Eur J Cancer. 2001;37:2349–56.PubMedCrossRef
Metadata
Title
Pretreatment quality of life and survival in patients with lung cancer: a systematic review and meta-analysis
Authors
Taro Okayama
Katsuyoshi Suzuki
Shinichiro Morishita
Junichiro Inoue
Takashi Tanaka
Jiro Nakano
Takuya Fukushima
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12267-w

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Methylation-regulated tumor suppressor gene PDE7B promotes HCC invasion and metastasis through the PI3K/AKT signaling pathway

Study Protocol

Habitat escalated adaptive therapy (HEAT): a phase 2 trial utilizing radiomic habitat-directed and genomic-adjusted radiation dose (GARD) optimization for high-grade soft tissue sarcoma

Research

Feasibility and safety of laparoscopic radical cystectomy for male octogenarians with muscle-invasive bladder cancer

Research

Using a combination of superb microvascular imaging and other auxiliary ultrasound techniques to increase the accuracy of gray-scale ultrasound for breast masses

Research

Investigating the causal role of the gut microbiota in esophageal cancer and its subtypes: a two-sample Mendelian randomization study

Research

High expression of TBRG4 in relation to unfavorable outcome and cell ferroptosis in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits